Skip to main content
NervGen Pharma Corp. logo

NervGen Pharma Corp. — Investor Relations & Filings

Ticker · NGEN ISIN · CA64082X2032 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 325 across all filing types
Latest filing 2025-11-24 Regulatory Filings
Country CA Canada
Listing TSXV NGEN

About NervGen Pharma Corp.

https://nervgen.com/

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on the discovery and development of pharmaceutical treatments designed to promote nervous system repair following neurologic trauma and disease. The company's core mission is to enable the nervous system to repair itself, offering a pharmacologic approach to conditions previously considered irreparable. Its lead drug candidate is NVG-291, a novel therapy currently in Phase 1b/2a clinical trials (CONNECT SCI Study) for individuals living with chronic spinal cord injury (SCI). Recent study data has demonstrated durable improvements in function and quality of life in this patient population. NervGen is also advancing its next-generation candidate, NVG-300, into preclinical proof-of-concept studies for three initial indications, expanding its pipeline for nervous system disorders.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109FV2', which is a standard officer certification for interim filings. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type (like an interim report), should be classified as Regulatory Filings (RNS) rather than the report itself, as they do not contain the actual financial statements or substantive financial data. 9M 2025
2025-11-24 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is explicitly titled 'Management's Discussion and Analysis' (MD&A) for NervGen Pharma Corp. for the three and nine months ended September 30, 2025. It provides a detailed assessment of financial conditions, results of operations, and forward-looking statements, which is the standard content for an MD&A report. According to the provided filing definitions, 'Management Reports' (MDA) is the specific category for a management's detailed explanation of financial results, business trends, and outlook.
2025-11-24 English
Interim financial statements/report – English.pdf
Regulatory Filings Classification · 1% confidence The document is a 'Consent of Qualified Person' form related to a NI 43-101 Technical Report. It is a short, formal legal document confirming the author's consent for the filing of a technical report and its summary in a press release. Since it does not fit into specific financial reporting categories like 10-K or IR, and is a standard regulatory requirement for technical filings, it falls under the general regulatory filings category.
2025-11-24 English
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a press release titled 'NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates'. It contains key financial highlights (cash position, R&D expenses, G&A expenses, net loss) for the quarter ended September 30, 2025, alongside business and pipeline updates. It is an initial announcement of quarterly results rather than a full interim report or a regulatory filing of a report. Therefore, it fits the definition of an Earnings Release (ER). Q3 2025
2025-11-24 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the closing of a US$10 million non-brokered private placement of units (shares and warrants). It details the use of proceeds, the participation of related parties, and the resulting change in shareholding for PFP Biosciences, which triggers an early warning report requirement. While it mentions an early warning report will be filed, the document itself is the primary announcement of the capital raise and the associated share issuance. Therefore, it is classified as a Capital/Financing Update (CAP).
2025-11-19 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a US$10 million non-brokered private placement of units (common shares and warrants) by NervGen Pharma. It details the financing structure, the intended use of proceeds, and the participation of related parties. This falls under the category of capital raising and financing activities. According to the provided definitions, 'Capital/Financing Update' (CAP) is the correct classification for updates on company fundraising and financing activities.
2025-11-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.